Overview

To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers

Status:
Completed

Trial end date:
2018-12-14

Target enrollment:

Participant gender:

Summary

Pancreatic, ovarian and colorectal cancers are difficult to treat using chemotherapy and immune therapies.Currently most patients are offered treatment with a standard chemotherapy drug depending on their cancer type. Recently, laboratory studies have shown that a drug called plerixafor may help the body to overcome resistance to immune therapy. The purpose of this study is to find out if the study drug has the same effect on patients with advanced pancreatic, ovarian or colorectal cancer, as we have seen in our laboratory experiments, and find out the right dose of the study drug to give. This is a 'dose escalation study'. Patients will be recruited slowly and the study team will closely monitor the effect the drug has, until they find the best dose to give. As part of this study, blood and tumour samples will be collected and analysed in our laboratories and the patients cancer will be monitored using two imaging techniques, CT and FDG-PET scans.

Phase:

Phase 1

Details

Lead Sponsor:

CCTU- Cancer Theme

Collaborators:

CRUK Cambridge Institute
Lustgarten Foundation
National Institute for Health Research, United Kingdom
Sanofi
Stand Up To Cancer

Treatments:

JM 3100
Plerixafor